Eosinophilic Biomarker Found for Aggressive IBD
|
By LabMedica International staff writers Posted on 14 Dec 2017 |
|
Image: Peripheral bloods smear showing five eosinophils, from a patient with eosinophilia (Photo courtesy of the Hospital for Sick Children, Toronto).
Peripheral blood eosinophilia (PBE) in inflammatory bowel disease is associated with ulcerative colitis (UC) and active disease. Little data exist on the long-term impact of PBE on disease course.
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Chromogenic Culture System
InTray™ COLOREX™ ECC
Latest Pathology News
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis and Management Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read more
Molecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read more
Pathology
view channel
FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Prostate cancer is the most common cancer among U.S. men, with more than 300,000 new cases and over 36,000 deaths each year. As targeted therapies emerge for biomarker-defined subgroups, laboratories need... Read more
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
